SB 201823-A | CAS#141429-64-3 | Ca2+ channel antagonist

MedKoo Cat#: 526253 | Name: SB 201823-A

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB 201823-A is a non-peptide Ca2+ channel antagonist. It is suggested that such novel neuronal Ca2+ channel antagonists may have potential in ameliorating both the pathological and functional consequences of stroke in man.

Chemical Structure

SB 201823-A

CAS#141429-64-3

Theoretical Analysis

MedKoo Cat#: 526253

Name: SB 201823-A

CAS#: 141429-64-3

Chemical Formula: C18H27Cl2NO

Exact Mass: 343.1470

Molecular Weight: 344.32

Elemental Analysis: C, 62.79; H, 7.90; Cl, 20.59; N, 4.07; O, 4.65

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SB 201823-A; SB201823A; SB-201823-A.

IUPAC/Chemical Name

4-(2-(3,4-Dichlorophenoxy)ethyl)-1-pentylpiperidine

InChi Key

DPNXGBOFZKMJSB-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H27Cl2NO.ClH/c1-2-3-4-10-21-11-7-15(8-12-21)9-13-22-16-5-6-17(19)18(20)14-16;/h5-6,14-15H,2-4,7-13H2,1H3;1H

SMILES Code

c1c(c(ccc1OCCC1CCN(CC1)CCCCC)Cl)Cl.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 344.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hicks CA, Ward MA, O'Neill MJ. Neuroprotective effects of the neuronal Ca(2+) channel blockers, LY042826 and LY393615 in vivo. Eur J Pharmacol. 2000 Nov 24;408(3):241-8. PubMed PMID: 11090640. 2: O'Neill MJ, Bath CP, Dell CP, Hicks CA, Gilmore J, Ambler SJ, Ward MA, Bleakman D. Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31. PubMed PMID: 9286613. 3: Barone FC, Lysko PG, Price WJ, Feuerstein G, al-Baracanji KA, Benham CD, Harrison DC, Harries MH, Bailey SJ, Hunter AJ. SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice. Stroke. 1995 Sep;26(9):1683-9; discussion 1689-90. PubMed PMID: 7660415. 4: Benham CD, Brown TH, Cooper DG, Evans ML, Harries MH, Herdon HJ, Meakin JE, Murkitt KL, Patel SR, Roberts JC, et al. SB 201823-A, a neuronal Ca2+ antagonist is neuroprotective in two models of cerebral ischaemia. Neuropharmacology. 1993 Nov;32(11):1249-57. PubMed PMID: 8107976.